PTEN expression is a strong predictor of survival in mesothelioma patients☆
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Malignant pleural mesothelioma (MPM) is a highly aggressive tumour with poor prognosis and limited response to therapy. MPM is characterised by complex chromosomal aberrations, including chromosome 10 losses. The tumour suppressor gene phosphatase and tensin homologue deleted from chromosome 10 (PTEN) located on chromosome 10q23 plays an important role in different cancer, but its relevance for MPM is unclear. PATIENTS AND METHODS: In the present tissue microarray-based study, 341 MPM were studied for PTEN expression by immunohistochemistry using a monoclonal mouse PTEN antibody. Expression levels were semiquantitatively scored (negative, weak, moderate, strong). Expression of PTEN was correlated to overall survival. RESULTS: Clinical data from 206 patients were available. One hundred and five patients were stage T4 and 92 patients presented with regional and mediastinal lymph node metastasis. Loss of PTEN expression was observed in 62% of the cases. The survival time was correlated to PTEN expression in 126 cases with complete follow-up data. Comparing any PTEN expression versus no expression, median survival time was significantly longer (log rank test p=0.0001) in patients with PTEN expression (15.5 months; 95% CI: 3.8; 27.2 vs 9.7 months; 95% CI: 7.9; 11.7). Cox regression analysis revealed an association between PTEN expression and survival (p=0.003) independently from the histological subtype (p=0.7). CONCLUSION: PTEN is an independent prognostic biomarker in mesothelioma patients. The frequent loss of expression of the tumour suppressor gene PTEN suggests involvement of the PI3K-AKT/protein kinase B (PKB) pathway in MPMs, which may be relevant for future mesothelioma treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 2×
“PTEN inactivation is probably the most common [20,21] as well as the most potent lesion of the oncogenic phosphatidylinositol-kinase (PI3K) signalling pathway, which has been implicated in nearly all aspects of tumour biology: cell transformation, growth, proliferation, migration, protection, apoptosis, genomic instab…”
BackgroundThe Multiple Roles of PTEN in Tumor Suppression
Di Cristofano, A., & Pandolfi, P. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80674-1 · Cited by 1,182
Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a
Janzen, V., Forkert, R., Fleming, H. E., Saito, Y., Waring, M. T., Dombkowski, D. M., Cheng, T., DePinho, R. A., Sharpless, N. E., & Scadden, D. T. (2006) · Nature · doi:10.1038/nature05159 · Cited by 1,106 · cited 1×
“PTEN inactivation is probably the most common [20,21] as well as the most potent lesion of the oncogenic phosphatidylinositol-kinase (PI3K) signalling pathway, which has been implicated in nearly all aspects of tumour biology: cell transformation, growth, proliferation, migration, protection, apoptosis, genomic instab…”
Background
Cited by
Malignant Pleural Mesothelioma
Tsao, A. S., Wistuba, I., Roth, J. A., & Kindler, H. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8523 · Cited by 481
Reactive Oxygen Species a Double-Edged Sword for Mesothelioma
Benedetti, S., Nuvoli, B., Catalani, S., & Galati, R. (2015) · Oncotarget · doi:10.18632/oncotarget.4253 · Cited by 97
“Malignant mesothelioma tumor specimens demonstrate high levels of phosphorylated Akt expression; in addition, a poor survival of malignant pleural mesothelioma (MPM) patients lacking PTEN expression has been observed [78, 84–85].”
BackgroundMesothelium and Malignant Mesothelioma
Hiriart, E., Deepe, R., & Wessels, A. (2019) · Journal of Developmental Biology · doi:10.3390/jdb7020007 · Cited by 66
“A number of studies have shown a loss of PTEN in mesothelioma and an associated overexpression of the PI3K/Akt/mTOR pathway [205,206].”
BackgroundTsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma
Guo, Y., Chirieac, L. R., Bueno, R., Pass, H., Wu, W., Malinowska, I. A., & Kwiatkowski, D. J. (2014) · Oncogene · doi:10.1038/onc.2013.280 · Cited by 26
Metadata
- Authors
- Opitz, I., Soltermann, A., Abaecherli, M., Hinterberger, M., Probst-Hensch, N., Stahel, R., Moch, H., & Weder, W.
- Venue
- European Journal of Cardio-Thoracic Surgery
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03
- Volume
- 33
- Issue
- 3
- Pages
- 502-506
- ISSN
- 1010-7940 (ISSN-L)
- OpenAlex
- W2117434848
- Cited by
- 82
- References
- 3
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.